BIMI (BIMI) Stock Price, News & Analysis

Company Overview

BIMI Holdings Inc., together with its subsidiaries, engages in the retail and wholesale distribution of medical devices, and pharmaceutical and other healthcare products in the People's Republic of China. The company operates in four segments: Wholesale Pharmaceuticals, Wholesale Medical Devices, Medical Services, and Retail Pharmacies. It distributes Stryker spinal products, Olympus endoscopes, imported imaging products, and diagnostic imaging equipment to drug stores, private clinics, pharmaceutical dealers, and hospitals in the Southwest region of the People's Republic of China. The company also distributes varieties of products, including raw ingredients for pharmaceutical products, antibiotics, cardiovascular drugs, and anti-obesity medicines. In addition, it offers prescription and over-the-counter drugs, nutritional supplements, traditional Chinese medicines, personal and family care products, medical devices, and miscellaneous items under the Lijiantang Pharmacy brand name. Further, the company provides medical services in the hospitals, as well as IT research and development services; and operates two private hospitals in China. It sells its medicine and other healthcare products to customers through its directly owned stores. The company was formerly known as BIMI International Medical Inc. and changed its name to BIMI Holdings Inc. in January 2024. BIMI Holdings Inc. was incorporated in 2000 and is headquartered in New York, New York.

Key Stats

• Today's Range: $0.02 to $0.02
• 50-Day Range: $0.01 to $1.45
• 52-Week Range: $0.00 to $4.13
• Volume: 2,067 shs
• Average Volume: 187,485 shs
• Market Capitalization: $231,800.00
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BIMI Stock Analysis - MarketRank™

BIMI scored higher than 9% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for BIMI.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

BIMI has a P/B Ratio of 0.01. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.18% of the float of BIMI has been sold short.

Short Interest Ratio / Days to Cover

BIMI has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BIMI has recently increased by 140.61%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BIMI does not currently pay a dividend.

Dividend Growth

BIMI does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.18% of the float of BIMI has been sold short.

Short Interest Ratio / Days to Cover

BIMI has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BIMI has recently increased by 140.61%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

2 people have added BIMI to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, BIMI insiders have not sold or bought any company stock.

Percentage Held by Insiders

69.02% of the stock of BIMI is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 0.11% of the stock of BIMI is held by institutions.

BIMI Stock Analysis - Frequently Asked Questions

How have BIMI shares performed this year?

BIMI's stock was trading at $2.19 on January 1st, 2024. Since then, BIMI stock has decreased by 99.1% and is now trading at $0.02.
View the best growth stocks for 2024 here.

When did BIMI's stock split?

BIMI's stock reverse split before market open on Monday, December 12th 2022. The 1-10 reverse split was announced on Monday, December 12th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, December 12th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of BIMI?

Shares of BIMI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of BIMI own?

Based on aggregate information from My MarketBeat watchlists, some other companies that BIMI investors own include iBio (IBIO), Airgain (AIRG), AIM ImmunoTech (AIM), Aytu BioPharma (AYTU), Nuwellis (CHFS), Clovis Oncology (CLVS) and

Company Calendar

• Today: 9/20/2024
• Next Earnings (Estimated): 11/27/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Drugs, proprietaries, & sundries
• Sub-Industry: Wholesale
• Current Symbol: NASDAQ:BIMI
• CUSIP: N/A
• CIK: 1213660
• Web: www.bimihc.com
• Phone: (212) 542-0028
• Fax: 86-24-8563-1159
• Employees: 520
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $12.63 million
• Price / Sales: 0.02
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.36 per share
• Price / Book: 0.01

Miscellaneous

• Outstanding Shares: 11,590,000
• Free Float: 3,591,000
• Market Cap: $231,800.00
• Optionable: Not Optionable
• Beta: 1.71